Synaptogenix (NASDAQ:TAOX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Synaptogenix (NASDAQ:TAOX) from a sell rating to a hold rating in a report published on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Synaptogenix Trading Down 6.2%

NASDAQ TAOX opened at $3.91 on Friday. Synaptogenix has a 12 month low of $1.84 and a 12 month high of $11.98. The stock has a 50-day simple moving average of $4.43 and a 200 day simple moving average of $6.07. The company has a market capitalization of $29.13 million, a PE ratio of -0.19 and a beta of 1.99.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.